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ABSTRACT
Objective This manuscript aims to explore the impact 
of race/ethnicity and socioeconomic status on in- hospital 
complication rates after left atrial appendage closure 
(LAAC).
Methods The US National Inpatient Sample was 
used to identify hospitalisations for LAAC between 1 
October 2015 to 31 December 2018. These patients 
were stratified by race/ethnicity and quartiles of median 
neighbourhood income. The primary outcome was the 
occurrence of in- hospital major adverse events, defined 
as a composite of postprocedural bleeding, cardiac and 
vascular complications, acute kidney injury and ischaemic 
stroke.
Results Of 6478 unweighted hospitalisations for LAAC, 
58% were male and patients of black, Hispanic and 
’other’ race/ethnicity each comprised approximately 
5% of the cohort. Adjusted by the older Americans 
population, the estimated number of LAAC procedures 
was 69.2/100 000 for white individuals, as compared 
with 29.5/100 000 for blacks, 47.2/100 000 for 
Hispanics and 40.7/100 000 for individuals of ’other’ 
race/ethnicity. Black patients were ~5 years younger but 
had a higher comorbidity burden. The primary outcome 
occurred in 5% of patients and differed significantly 
between racial/ethnic groups (p<0.001) but not across 
neighbourhood income quartiles (p=0.88). After 
multilevel modelling, the overall rate of in- hospital major 
adverse events was higher in black patients as compared 
with whites (OR: 1.60, 95% CI 1.22 to 2.10, p<0.001); 
however, the incidence of acute kidney injury was higher 
in Hispanics (OR: 2.19, 95% CI 1.52 to 3.17, p<0.001). 
No significant differences were found in adjusted overall 
in- hospital complication rates between income quartiles.
Conclusion In this study assessing racial/ethnic 
disparities in patients undergoing LAAC, minorities are 
under- represented, specifically patients of black race/
ethnicity. Compared with whites, black patients had 
higher comorbidity burden and higher rates of in- hospital 
complications. Lower socioeconomic status was not 
associated with complication rates.
INTRODUCTION
Patients with atrial fibrillation (AF) are at a signifi-
cantly elevated risk of embolic stroke,1 and oral 
anticoagulation therapy is the mainstay for its 
prevention. However, many patients with AF are 
not candidates for anticoagulation because they 
have contraindications such as prior bleeding 
episodes or suboptimal management. In those situ-
ations, left atrial appendage closure (LAAC) is a 
non- pharmacological option to reduce the risk of 
stroke.2 3
Previous studies have shown that racial and socio-
economic disparities exist in both AF management 
and structural heart disease interventions,4 5 but how 
these inequalities influence individuals undergoing 
LAAC is not fully understood. As LAAC procedures 
continue to increase, it is important to understand 
the characteristics of the patients receiving the 
procedure and whether factors exist that impact 
postprocedural outcomes. With that information, 
physicians can both select patients who may derive 
the optimal benefit from the procedure, while at the 
same time make efforts to reduce factors that lead 
to inequalities in access and outcomes. Therefore, 
we aimed to explore the impact of self- reported 
race/ethnic and socioeconomic status on in- hospital 
complication rates in individuals undergoing LAAC.
METHODS
Data source and study population
The data source for this study was the National 
Inpatient Sample (NIS), a US all- payer inpatient 
healthcare database.6 All hospitalisations in the NIS 
who had undergone LAAC, as a primary proce-
dure, between 1 October 2015 and 31 December 
2018 were included in the study. Eligible partici-
pants were identified with the International Clas-
sification of Diseases 10th Revision (ICD-10) 
procedure code 02L73DK (occlusion of left atrial 
appendage with Watchman device (Boston Scien-
tific, Natick, Massachusetts, USA), percutaneous 
approach). Information on patients’ demographics 
was extracted from the database, including age, sex, 
race and median household income according to 
residential zip code. Patient records were excluded 
from the cohort if they did not include race or zip 
code income quartile.
The CHA2DS2- VASc score was used to categorise 
preprocedural thromboembolic risk; its compo-
nents include congestive heart failure, hyperten-
sion, age 65 to 74 years and ≥75 years, diabetes 
mellitus, prior stroke or transient ischemic attack 
(TIA), vascular disease (including previous myocar-
dial infarction) and female sex.7 8 The Charlson 
comorbidity index (CCI) and Elixhauser comor-
bidity score (ECS) were used to assess the comor-
bidity burden.9–14 These comorbidity measurements 
 on M














2 Sparrow R, et al. Heart 2021;0:1–10. doi:10.1136/heartjnl-2020-318650
Arrhythmias and sudden death
were calculated by identifying the ICD-10 codes, which corre-
sponded to each component of the scores.
Study outcomes
The primary study outcome was the occurrence of in- hospital 
complication, defined as the composite of bleeding complica-
tions, cardiac complications, vascular complications, acute 
kidney injury (AKI) and postprocedural stroke or TIA. Only 
ICD-10 codes that explicitly referenced postprocedural haem-
orrhage or haematoma were included in bleeding complications. 
Cardiac complications included myocardial infarction, pericar-
dial complications, complete heart block, cardiogenic shock and 
need for emergency open cardiac surgery. In- hospital complica-
tions were identified using ICD-10 codes, in the same manner 
as described above for comorbidities and are detailed in online 
supplemental table 1.
Statistical analysis
The study population was stratified by self- reported race/
ethnicity and by quartiles of median household income according 
to zip code. The NIS database categorises individuals into six 
racial groups: white, black, Hispanic, Asian/Pacific Islander, 
Native American and ‘other’. The first three groups were left 
unchanged for this study, and the last three were combined into 
an ‘other race/ethnicity’ group due to low numbers of patients in 
each individual group. Median zip code incomes were $0–$45 
999, $46 000–$58 999, $59 000–$78 999 and above $79 000 
for quartiles 1–4 in 2018, respectively.
Comparisons were performed between the baseline character-
istics of each racial group and each zip code income quartile, 
respectively. Categorical variables were expressed as counts and 
proportions and were analysed using χ2 or Fisher’s exact test. 
Continuous variables are expressed median (IQR) given their 
non- normal distribution. The Kruskal- Wallis test was used to 
compare differences between groups, and pair- wise compari-
sons of racial/ethnic group ages were evaluated with the Mann- 
Whitney U test with Bonferroni correction. Table cells with less 
than 10 discharge records are displayed as ‘<10’ because the 
exact count could not be reported under the Healthcare Cost 
and Utilization Project data use agreement. Adjusted p values 
for each variable were computed adjusting for a survey sampling 
design by discharge- level weights, cluster and strata provided by 
NIS and recommended by the Agency for Healthcare Research 
and Quality during survey- specific analysis.15
The Cochran- Armitage trend test was used for detecting linear 
trends for changes in the number of LAAC procedures among 
individuals of white versus non- white race/ethnicity over the 
time. Length of stay (LOS) was calculated by subtracting the 
admission date from the discharge date.
Because the NIS database has a two- level hierarchical struc-
ture (patients are nested within hospitals), to account for intra-
cluster correlation within hospitals, multilevel modelling was 
performed to allow the intercepts to vary across hospitals and 
sampling weights were adjusted. The associations between race/
ethnicity and income quartiles, and in- hospital complications 
were assessed using multilevel multivariable logistic regression 
models adjusted for age, sex and relevant comorbidities. The 
models stratified by racial/ethnic groups were adjusted by median 
neighbourhood income quartiles, and conversely, the models 
stratified by income quartiles were adjusted by race. Relevant 
comorbidities were selected a priori based on their clinical signif-
icance that may directly influence in- hospital outcomes and also 
those with a p value <0.10 as determined by univariable anal-
ysis (online supplemental table 2). Two similar models were used 
to assess the impact of individual comorbidities on in- hospital 
complications, one of which was adjusted by race/ethnicity and 
the other by income quartiles. White patients and those from 
the top income quartile were used as reference groups for all 
Figure 1 Quarterly number of LAAC procedures performed (red/navy) for patients of white and non- white race/ethnicity and yearly proportion 
of patients from urban versus rural regions (green). Cochran- Armitage trend test demonstrated no statistically significant difference in procedures 
performed over the time between white and non- white race/ethnicity (Ptrend=0.95). Significant change in the proportion of patients from urban versus 
rural regions was observed over the time (p=0.015). The right- hand y- axis does not start from zero. LAAC, left atrial appendage closure.
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Table 1 Baseline characteristics of the study population stratified by race/ethnicity
Patient characteristics All n=6478 White n=5585 Black n=278 Hispanic n=376 Other n=239 P value Adjusted p value*
Age (years) 77 (71–82) 77 (72–82) 72 (66–78) 77 (71–82) 75 (68–82) <0.001 <0.001
Sex, male 3781 (58) 3299 (59) 128 (46) 212 (56) 142 (59) <0.001 <0.001
Median household income
  0–25th percentile 1311 (20) 1038 (19) 131 (47) 108 (29) 34 (14) <0.001 <0.001
  26–50th percentile 1679 (26) 1492 (27) 57 (21) 88 (23) 42 (18)
  51–75th percentile 1803 (28) 1572 (28) 54 (19) 108 (29) 69 (29)
  76–100th percentile 1685 (26) 1483 (27) 36 (13) 72 (19) 94 (39)
Patient location
  Urban† 5480 (85) 4670 (84) 255 (92) 337 (90) 218 (91) <0.001 <0.001
  Rural 998 (15) 915 (16) 23 (8.3) 39 (10) 21 (8.8)
Hospital teaching status and location
  Rural 112 (1.7) 112 (2.0) <10 (0) <10 (0) <10 (0) <0.001 <0.001
  Urban non- teaching 561 (8.7) 496 (8.9) 18 (6.5) 32 (8.5) 15 (6.3)
  Urban teaching 5805 (90) 4977 (89) 260 (94) 344 (91) 224 (94)
Hospital bed size
  Small 671 (10) 555 (9.9) 22 (7.9) 62 (16) 32 (13) 0.002 <0.001
  Medium 1370 (21) 1190 (21) 60 (22) 69 (18) 51 (21)
  Large 4437 (68) 3840 (69) 196 (71) 245 (65) 156 (65)
Primary payer*
  Medicare 5744 (89) 5013 (90) 224 (81) 310 (82) 197 (82) <0.001 <0.001
  Medicaid 75 (1.2) 37 (0.7) 14 (5.0) 15 (4.0) <10 (3.8)
  Private insurance 529 (8.2) 432 (7.8) 28 (10) 42 (11) 27 (11)
  Other 118 (1.8) 91 (1.6) 12 (4.3) 9 (2.4) <10 (2.5)
Comorbidities
Smoking 2262 (35) 1989 (36) 98 (35) 91 (24) 84 (35) <0.001 <0.001
Dyslipidaemia 3883 (60) 3349 (60) 170 (61) 225 (60) 139 (58) 0.92 0.92
Renal 667 (10) 555 (10) 47 (17) 33 (9) 32 (13) <0.001 <0.001
Previous CABG 977 (15) 864 (15) 21 (8) 63 (17) 29 (12) 0.002 0.001
Hypertension 5575 (86) 4771 (85) 263 (95) 337 (90) 204 (85) <0.001 <0.001
Diabetes mellitus 2242 (35) 1871 (34) 115 (41) 162 (43) 94 (39) <0.001 <0.001
Obesity 1085 (17) 933 (17) 63 (23) 62 (16) 27 (11) 0.01 0.01
Congestive heart failure 2488 (38) 2110 (38) 141 (51) 144 (38) 93 (39) <0.001 <0.001
Myocardial infarction 821 (13) 706 (13) 37 (13) 49 (13) 29 (12) 0.98 0.98
Peripheral vascular disease 685 (11) 601 (11) 30 (11) 31 (8) 23 (10) 0.46 0.46
Cerebrovascular disease 1859 (29) 1566 (28) 95 (34) 111 (30) 87 (36) 0.01 0.01
Valvular disease 1365 (21) 1208 (22) 63 (23) 51 (14) 43 (18) 0.001 0.001
COPD 1419 (22) 1223 (22) 86 (31) 75 (20) 35 (15) <0.001 <0.001
Rheumatic disease 188 (2.9) 160 (2.9) 11 (4) 12 (3.2) <10 (2.1) 0.59 0.62
Liver disease 173 (2.7) 134 (2.4) <10 (3.2) 20 (5.3) 10 (4.2) 0.004 0.003
Hypothyroidism 1100 (17) 977 (17) 29 (10) 65 (17) 29 (12) 0.004 0.004
Cancer 149 (2.3) 126 (2.3) <10 (2.9) <10 (2.4) <10 (2.5) 0.83 0.91
Anaemia 496 (7.7) 412 (7.4) 38 (14) 30 (8.0) 16 (6.7) 0.004 0.002
Depression 484 (7.5) 429 (7.7) 19 (6.8) 27 (7.2) <10 (3.8) 0.15 0.15
Charlson comorbidity index 2 (1–3) 2 (1–3) 3 (1–4) 2 (1–3) 2 (1–3.5) <0.001 <0.001
Elixhauser comorbidity score 8 (5–13) 8 (5–13) 12 (6–17) 9 (5–13.25) 10 (5–14) <0.001 <0.001
CHA2DS2- VASc 4 (3–5) 4 (3–5) 4 (3–5.75) 4 (3–5) 4 (3–5) 0.03 0.03
  ≥2 (High) 6333 (97.8) 5463 (97.8) 275 (98.9) 367 (97.6) 228 (95.4) 0.07 0.18
Year of procedure
2015 (October–December) 111 (1.7) 91 (1.6) <10 (1.8) <10 (2.4) <10 (2.5) <0.001 <0.001
2016 (January–December) 960 (15) 838 (15) 33 (12) 34 (9) 55 (23)
2017 (January–December) 2054 (32) 1770 (32) 89 (32) 122 (32) 73 (31)
2018 (January–December) 3353 (52) 2886 (52) 151 (54) 211 (56) 105 (44)
Length of stay (days, range) 0–35 0–35 0–26 0–25 0–11 – –
Length of stay (days, median) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) <0.001 <0.001
  ≤1 day 5555 (86) 4840 (87) 210 (76) 310 (82) 195 (82) <0.001 <0.001
  >1 day 923 (14) 745 (13) 68 (24) 66 (18) 44 (18)











Deaths <10 (0.1) <10 (0.2) <10 (0) <10 (0) <10 (0) >0.99 0.69
Values are expressed as median (IQR) or counts (%). Exact counts for variables with <10 patients are not detailed as per the Healthcare Cost and Utilization Project data use agreement.
Bold type indicates significant p values (<0.05).
*Adjusted p values for each variable were computed from adjusting sampling design by discharge- level weights, cluster and strata.
†Total cost was missing 0.6%.
‡Primary payer was missing in 0.1%.
§Urban location was defined as counties in metro areas of >50 000 population.
CABG, coronary artery bypass surgery; CHA2DS2- VASc, congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke or transient ischaemic attack, vascular disease (including previous myocardial infarction), age 65–74 years, sex 
category; COPD, chronic obstructive pulmonary disease.
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Table 2 Baseline characteristics of the study population stratified by median household income
Patient characteristics All n=6478
Quartile 1
n=1311 Quartile 2 n=1679 Quartile 3 n=1803 Quartile 4 n=1685 P value
Adjusted p 
value*
Age (years) 77 (71–82) 76 (71–81) 77 (71–82) 77 (71–82) 77 (71–82) 0.004 0.003
Sex, male 3781 (58) 713 (54) 973 (58) 1052 (58) 1043 (62) <0.001 <0.001
Race
  White 5585 (86) 1038 (79) 1492 (89) 1572 (87) 1483 (88) <0.001 <0.001
  Black 278 (4.3) 131 (10) 57 (3.4) 54 (3.0) 36 (2.1)
  Hispanic 376 (5.8) 108 (8.2) 88 (5.2) 108 (6.0) 72 (4.3)
  Other 239 (3.7) 34 (2.6) 42 (2.5) 69 (3.8) 94 (5.6)
Patient location
  Urban† 5480 (85) 831 (63) 1280 (76) 1694 (94) 1675 (99) <0.001 <0.001
  Rural 998 (15) 480 (37) 399 (24) 109 (6.0) 10 (0.6)
Hospital teaching status and location
  Rural 112 (1.7) 38 (2.9) 56 (3.3) 18 (1.0) <10 (0) <0.001 <0.001
  Urban non- teaching 561 (8.7) 108 (8.2) 137 (8.2) 149 (8.3) 167 (9.9)
  Urban teaching 5805 (90) 1165 (89) 1486 (89) 1636 (91) 1518 (90)
Hospital bed size
  Small 671 (10) 140 (11) 167 (9.9) 204 (11) 160 (9.5) 0.32 0.28
  Medium 1370 (21) 286 (22) 374 (22) 372 (21) 338 (20)
  Large 4437 (68) 885 (68) 1138 (68) 1227 (68) 1187 (70)
Primary payer*
  Medicare 5744 (89) 1155 (88) 1497 (89) 1619 (90) 1473 (87) 0.02 0.05
  Medicaid 75 (1.2) 25 (1.9) 21 (1.3) 13 (0.7) 16 (1.0)
  Private insurance 529 (8.2) 98 (7.5) 127 (7.6) 145 (8.1) 159 (9.4)
  Other 118 (1.8) 29 (2.2) 29 (1.7) 24 (1.3) 36 (2.1)
Comorbidities
Smoking 2262 (35) 464 (35) 587 (35) 618 (34) 593 (35) 0.92 0.92
Dyslipidaemia 3883 (60) 775 (59) 1024 (61) 1056 (59) 1028 (61) 0.34 0.34
Renal disease 667 (10) 139 (11) 161 (10) 203 (11) 164 (10) 0.28 0.28
Previous CABG 977 (15) 192 (15) 256 (15) 279 (15) 250 (15) 0.91 0.91
Hypertension 5575 (86) 1153 (88) 1444 (86) 1532 (85) 1446 (86) 0.12 0.12
Diabetes mellitus 2242 (35) 492 (38) 611 (36) 604 (33) 535 (32) 0.002 0.002
Obesity 1085 (17) 239 (18) 293 (17) 289 (16) 264 (16) 0.19 0.19
Congestive heart failure 2488 (38) 541 (41) 651 (39) 706 (39) 590 (35) 0.004 0.004
Myocardial infarction 821 (13) 182 (14) 227 (14) 229 (13) 183 (11) 0.05 0.05
Peripheral vascular disease 685 (11) 139 (11) 190 (11) 202 (11) 154 (9.1) 0.14 0.14
Cerebrovascular disease 1859 (29) 390 (30) 455 (27) 520 (29) 494 (29) 0.37 0.37
Valvular disease 1365 (21) 281 (21) 354 (21) 355 (20) 375 (22) 0.31 0.31
Dementia 177 (2.7) 37 (2.8) 49 (2.9) 36 (2) 55 (3.3) 0.13 0.13
COPD 1419 (22) 321 (24) 406 (24) 382 (21) 310 (18) <0.001 <0.001
Rheumatic disease 188 (2.9) 42 (3.2) 43 (2.6) 58 (3.2) 45 (2.7) 0.56 0.56
Liver disease 173 (2.7) 41 (3.1) 46 (2.7) 49 (2.7) 37 (2.2) 0.46 0.46
Hypothyroidism 1100 (17) 222 (17) 277 (16) 340 (19) 261 (15) 0.06 0.06
Cancer 149 (2.3) 22 (1.7) 42 (2.5) 49 (2.7) 36 (2.1) 0.24 0.24
Anaemia 496 (7.7) 103 (7.9) 136 (8.1) 132 (7.3) 125 (7.4) 0.81 0.81
Depression 484 (7.5) 79 (6) 131 (7.8) 166 (9.2) 108 (6.4) 0.002 0.002
Charlson comorbidity index 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–3) 1 (1–3) <0.001 <0.001
Elixhauser comorbidity score 8 (5–13) 10 (5–14) 9 (5–13) 9 (5–13) 8 (5–12) 0.002 0.002
CHA2DS2- VASc 4 (3–5) 4 (3–5) 4 (3–5) 4 (3–5) 4 (3–5) 0.01 0.01
  ≥2 (high) 6333 (98) 1279 (98) 1641 (98) 1766 (98) 1647 (98) 0.91 0.19
Year of procedure
2015 (October–December) 111 (1.7) 20 (1.5) 25 (1.5) 26 (1.4) 40 (2.4) <0.001 <0.001
2016 (January–December) 960 (15) 172 (13) 222 (13) 265 (15) 301 (18)
2017 (January–December) 2054 (32) 431 (33) 521 (31) 594 (33) 508 (30)
2018 (January–December) 3353 (52) 688 (52) 911 (54) 918 (51) 836 (50)
Length of stay (days, range) 0–35 0–26 0–35 0–27 0–21 – –
Length of stay (days, median) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 0.01 0.01
  ≤1 day 5555 (86) 1099 (84) 1450 (86) 1534 (85) 1472 (87) 0.03 0.03
  >1 day 923 (14) 212 (16) 229 (14) 269 (15) 213 (13)
Continued
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adjustments. Results are presented as OR with 95% CI. All p 
values are two sided with a significance threshold of <0.05. 
Statistical analyses were performed using R V.3.6.3.16
Patient and public involvement
There were no patients or the public involved around the research 
question or conception and design of the study. Because of the 
nature of the study, patients or public were not involved in any 
recruitment or conduction of the study. No patients or public 
were involved in measuring the outcomes, nor were asked to 
provide interpretations of the findings or writing of the results.
RESULTS
Study population
A total of 6779 unweighted hospitalisations were identified; of 
these, 204 (3.0%) were excluded due to missing racial/ethnic 
group data, and 93 (1.4%) were excluded due to missing income 
quartile data and 4 (0.05%) for missing both variables, leaving 
6478 patients for the final analysis. In this final cohort, 3781 
(58%) were men and 5585 (86%) were of white ethnicity. Black, 
Hispanic and patients of ‘other’ race/ethnicity each comprised 
less than 5% of the total cohort. The number of LAAC proce-
dures performed on patients of each racial/ethnic group was 
divided by the total population of individuals over the age 65 
years of each ethnicity in the USA, after adjustment for sampling 
design and discharge weights.17 The estimated number of LAAC 
procedures was 69.2/100 000 for white individuals, as compared 
with 29.5/100 000 for blacks, 47.2/100 000 for Hispanics and 
40.7/100 000 for individuals of ‘other’ race/ethnicity.
A quarterly analysis was conducted to compare the number of 
procedures performed on patients of white and non- white race/
ethnicity over time (figure 1). Based on the Cochrane- Armitage 
trend test, there were no statistical differences in the propor-
tion of LAAC performed on patients of white versus non- white 
race/ethnicity (Ptrend=0.95). In addition, no statistical differences 
were observed in procedures performed among individuals of 
white, black and Hispanic race/ethnicity over time (p=0.27 for 
whites vs blacks, and p=0.06 for whites vs Hispanics). Figure 1 
also displays the changes in the distribution of LAAC procedures 
performed in patients living in urban versus rural regions, impor-
tantly, there was a significant increase (p=0.015) over time in 
the proportion of patients from rural regions receiving LAAC.
Baseline characteristics stratified by race and zip code income 
quartile are presented in tables 1 and 2, respectively. Several 
important differences were found between the racial/ethnic 
groups. A significant difference was found in the median age 
Patient characteristics All n=6478
Quartile 1
n=1311 Quartile 2 n=1679 Quartile 3 n=1803 Quartile 4 n=1685 P value
Adjusted p 
value*











Deaths <10 (0.2) <10 (0.3) <10 (0.3) <10 (0.1) 0 (0) 0.31 0.40
Values are expressed as median (IQR) or counts (%). Exact counts for variables with <10 patients are not detailed as per the Healthcare Cost and Utilization Project data use agreement.
Bold type indicates significant p values (<0.05).
*Adjusted p values for each variable were computed from adjusting sampling design by discharge- level weights, cluster and strata.
†Total cost was missing 0.6%.
‡Primary payer was missing in 0.1%.
§Urban location was defined as counties in metro areas of >50 000 population.
CABG, coronary artery bypass surgery; CHA2DS2- VASc, congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke or transient ischaemic attack, vascular disease (including 
previous myocardial infarction), age 65–74 years, sex category; COPD, chronic obstructive pulmonary disease.
Table 2 Continued
Table 3 In- hospital major adverse events
Stratified by race/ethnic groups
In- hospital major adverse events All n=6478 White n=5585 Black n=278 Hispanic n=376 Other n=239 P value
Adjusted
p value*
Overall major adverse events† 323 (5.0) 258 (4.6) 26 (9.4) 27 (7.2) 12 (5.0) <0.001 <0.001
  Bleeding complications 37 (0.6) 30 (0.5) <10 (0.4) <10 (1.1) <10 (0.8) 0.37 0.52
  Cardiac complications 132 (2.0) 113 (2.0) <10 (2.2) <10 (1.6) <10 (2.9) 0.67 0.72
  Vascular complications 27 (0.4) 25 (0.4) <10 (0.4) <10 (0.3) <10 (0) 0.95 0.72
  Stroke/TIA 21 (0.3) 19 (0.3) <10 (0.4) <10 (0.3) <10 (0) 0.94 0.83
  Acute kidney injury 151 (2.3) 113 (2.0) 18 (6.5) 15 (4.0) <10 (2.1) <0.001 <0.001
Stratified by income quartiles
In- hospital major adverse events All n=6478 Quartile 1
n=1311
Quartile 2 n=1679 Quartile 3 n=1803 Quartile 4 n=1685 P value Adjusted p value
Overall major adverse events† 323 (5.0) 64 (4.9) 85 (5.1) 95 (5.3) 79 (4.7) 0.88 0.88
  Bleeding complications 37 (0.6) <10 (0.5) 12 (0.7) 13 (0.7) <10 (0.3) 0.29 0.31
  Cardiac complications 132 (2.0) 22 (1.7) 38 (2.3) 41 (2.3) 31 (1.8) 0.55 0.55
  Vascular complications 27 (0.4) <10 (0.5) 10 (0.6) <10 (0.2) <10 (0.3) 0.37 0.39
  Stroke/TIA 21 (0.3) <10 (0.3) <10 (0.4) <10 (0.3) <10 (0.3) 0.92 0.89
  Acute kidney injury 151 (2.3) 34 (2.6) 31 (1.8) 45 (2.5) 41 (2.4) 0.49 0.49
Values are expressed as counts (%). Exact counts for variables with <10 patients are not detailed as per the Healthcare Cost and Utilization Project data use agreement.
Bold type indicates significant p values (<0.05).
*Adjusted p values for each variable were computed from adjusting sampling design by discharge- level weights, cluster and strata.
†Numbers/percentages may not add up since several patients experienced more than one complication.
TIA, transient ischaemic attack.
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of patients of each racial/ethnic group (p<0.001). In particular, 
the median age of blacks was 5 years younger than that of white 
patients (77 (72–82) vs 72 (66–78) years, p<0.001 using Mann- 
Whitney U test with Bonferroni correction). Around 55% of the 
patients lived in neighbourhoods in the upper half of household 
incomes, with 1083 (28%) and 1685 (26%) coming from the 
third and fourth quartiles, respectively, and 37% of patients 
living in zip code median income quartile 1 lived in a rural region 
(table 2). Most (90%) of the LAAC procedures were performed 
in urban- teaching hospitals. The primary payer was significantly 
different among racial/ethnic groups (p<0.001); interestingly, 
private insurance was found more frequently among minorities 
(table 1).
There were significant differences in median CCI (p<0.001), 
ECS (p<0.001) and CHA2DS2- VASc scores (p=0.03) of each 
racial/ethnic group. These differences were driven by differ-
ences in several comorbidities, including renal disease, hyperten-
sion, congestive heart failure and anaemia, with black patients 
having significantly higher prevalence of each of these comor-
bidities (p<0.05 for all). Median LOS differed between groups 
(p<0.001) and hence index hospitalisation costs also tend to 
differ (p=0.05), with blacks having the highest median costs 
compared with the other races (table 1).
Significant differences were also found between the patients 
in each zip code household income quartile. Among these, the 
median CCI (p<0.001), ECS (p=0.002) and CHA2DS2- VASc 
(p=0.01) scores differed between income quartiles. Median 
LOS (p=0.01) was also significantly different, and index hospi-
talisation costs increased significantly as neighbourhood incomes 
increased from quartile 1 to quartile 4 ($23 608 vs $23 983 vs 
$25 054 vs $24 920, p<0.001) (table 2).
In-hospital complications
The primary composite outcome of in- hospital major adverse 
events occurred in 323 (5.0%) patients and differed significantly 
between racial/ethnic groups (4.6% in whites vs 9.4% in blacks 
vs 7.2% in Hispanics, p<0.001) but not zip code income quar-
tiles (p=0.88). In- hospital complication rates stratified by race/
ethnicity and neighbourhood income quartiles are shown in 
table 3. Notably, the occurrence of stroke/TIA and death were 
low, with incidences of 0.3% and 0.2%, respectively. Of the indi-
vidual complications, only AKI differed significantly (p<0.001), 
while there were no significant differences within the income 
quartile analysis.
After multilevel modelling with adjustment for rele-
vant comorbidities and neighbourhood income quartiles 
(figure 2A), the overall rate of in- hospital major adverse 
events was higher in black patients as compared with whites 
(OR: 1.60, 95% CI 1.22 to 2.10, p<0.001) while lower in 
patients of ‘Other’ race/ethnicity (OR: 0.65, 95% CI 0.45 to 
0.94, p=0.02). Among the individual in- hospital complica-
tions, AKI was more commonly observed among Hispanics 
(OR: 2.19, 95% CI 1.52 to 3.17, p<0.001), while the rate 
of cardiac complications was lower (OR: 0.34, 95% CI 0.21 
to 0.55, p<0.001). No statistical differences were found 
among the individual components of the composite endpoint 
between white and black patients.
No statistical differences were found in adjusted overall 
in- hospital complication rates between neighbourhood income 
quartiles (figure 2B). However, among the individual compo-
nents of the composite endpoint, the rates of cardiac complica-
tions were lower in quartile 1 as compared with quartile 4 (OR: 
0.65, 95% CI 0.47 to 0.90, p=0.01), and the rates of bleeding 
complications were higher in quartile 3 (p<0.001) and quar-
tile 2 (p<0.001). An ad hoc sensitivity analysis was performed 
to determine the effect that adjustment by racial/ethnic and 
neighbourhood income quartile had on their corresponding 
model. After removing these variables and adjusting in- hos-
pital outcomes only by age, sex and relevant comorbidities, no 
differences were found in the significance of the racial/ethnic 
group or income quartile stratified outcomes (figure 3). Post hoc 
sensitivity analysis for multilevel multivariable models adjusted 
by comorbidities with univariable p value <0.2 was performed, 
and no differences in the significance of any complication rate 
was found (online supplemental table 3).
The results of the multilevel multivariable model assessing 
the impact of preprocedural comorbidities on total compli-
cation rates are displayed in figure 4. After adjusting for 
race/ethnicity, the presence of preprocedural anaemia had 
the largest impact on the risk of in- hospital complications 
(OR: 2.24, 95% CI 1.87 to 2.69, p<0.001), followed by 
renal disease (OR: 1.78, 95% CI 1.64 to 1.94) (figure 4A). 
Sensitivity analysis with adjustment by race/ethnicity alone 
Figure 2 Forest plot showing multilevel multivariable regression 
analysis for in- hospital major adverse events adjusted by age, sex, 
relevant comorbidities, and racial/ethnic and neighbourhood income 
quartiles. (A) Stratified by racial/ethnic groups and adjusted by zip code 
median household income quartiles. (B) Stratified by zip code median 
household income quartiles and adjusted by racial/ethnic groups. TIA, 
transient ischaemic attack.
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(figure 4B) and neighbourhood income quartiles alone 
(figure 4B) yielded almost identical results.
DISCUSSION
In this cohort- based observational study of 6478 hospitalisa-
tions for LAAC, 86% were of white race/ethnicity and about 
half lived in neighbourhoods below the median income level. 
The primary outcome of overall in- hospital major adverse 
events occurred in 5% of patients, and an analysis of the 
distribution of these complications yielded several important 
results. First, black patients tended to have higher prepro-
cedural burden of comorbidities compared with other races. 
Second, black patients had significantly higher complication 
rates as compared with whites, both, before and after adjust-
ment for relevant clinical variables. Third, the presence of 
baseline congestive heart failure, chronic kidney disease and 
anaemia were strongly associated with in- hospital complica-
tions in the overall cohort. Finally, low socioeconomic status, 
as measured by median neighbourhood income, was not asso-
ciated with higher rates of in- hospital complication following 
LAAC. Figure 5 displays a summary of these findings.
Disparities in LAAC
An important finding of this study is that black and Hispanic 
patients were under- represented compared with the propor-
tion of US individuals that are aged over 65 years old. Indeed, 
a report from the US Department of Health and Human 
Services showed that in 2018, 23% of individuals aged 65 years 
and older were part of a racial/ethnic minority, among those, 
blacks and Hispanics accounted for 12% and 7%, respectively.17 
Therefore, cosidering a population of US individuals aged 65 
years and older, the number of LAAC procedures performed in 
white patients was 2.3 times that of blacks and 1.5 times that of 
Hispanics.
Racial disparities in the utilisation of other cardiac proce-
dures, including transcatheter aortic valve implantation, have 
previously been documented.18 Our results indicate that 
disparities exist to a similar extent for LAAC, and there are 
likely multiple explanations for these differences. On one 
Figure 3 Forest plots showing a sensitivity analysis to determine 
the effect that adjustment by racial/ethnic and neighbourhood income 
quartiles had on their corresponding model for in- hospital major 
adverse events. Multilevel multivariable regression analysis adjusted 
by age, sex and relevant comorbidities. (A) Stratified by racial/ethnic 
groups. (B) Stratified by zip code median household income quartiles. 
TIA, transient ischaemic attack.
Figure 4 Forest plot showing multilevel multivariable regression 
analyses for comorbidities associated with in- hospital major adverse 
events. (A) Adjusted by racial/ethnic groups and median household 
income quartiles. (B) Sensitivity analysis adjusted by racial/ethnic groups 
and (C) by median household income quartiles.
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hand, it is known that the incidence of AF is lower in black 
and Hispanic individuals as compared with whites counter-
parts.19 20 However, previous studies have also shown that 
AF management and anticoagulation among racial minorities 
are less likely to follow guideline- directed medical therapy, 
and lower LAAC rates could be an extension of these dispari-
ties.4 21 In this regard, Essien et al22 assessed whether contra-
indications to oral anticoagulation differ by racial group and 
found no significant differences, suggesting that the propor-
tion of patients with AF that would qualify for LAAC should 
be broadly similar across racial groups. Moreover, the use of 
new technologies tends to occur in large university hospital 
centres located in urban areas, which may have more diverse 
populations compared with smaller rural hospitals. Notably, 
another important finding of this study is the increased 
proportion of individuals located in rural regions, high-
lighting an improvement in access to LAAC over the study 
period.
Socioeconomic status is often related to racial/ethnic 
disparities. In fact, Sleder et al23 showed that even in an urban 
academic medical centre, patients of lower income status 
and black race/ethnicity were less likely to undergo tran-
scatheter aortic valve implantation, and this gap remained 
after adjusting for age and comorbidities. The authors also 
found that black patients with severe aortic stenosis often 
decline aortic valve replacement when recommended,23 
raising concerns about historical discrimination, trust and the 
delivery of care.23–26
Our study also indicates that black patients receiving LAAC 
were over 5 years younger than those in other racial/ethnic 
groups. However, despite their younger age, black patients 
still presented with a higher burden of comorbidities, and 
this is in line with previous data showing that black patients 
undergoing LAAC have higher ECS and hospitalisation costs.5 
As the number of black and Hispanic patients undergoing 
LAAC increased over time, future research may be able to 
confirm that this higher burden of comorbidities is correlated 
with significant impact on postprocedural outcomes.
In contrast to this body of research about racial dispari-
ties, less is known about socioeconomic disparities in AF and 
transcatheter- based cardiac interventions. A case–control 
study with 201 patients demonstrated that patients undergoing 
LAAC were of higher income level than those who did not,27 
but no previous studies have analysed the effect of socioeco-
nomic status on LAAC outcomes. Our study shows no impact 
on neighbourhood income on any postprocedural outcomes, 
but further research is likely needed to assess the impact of 
other indicators of socioeconomic status such as education and 
personal incomes.
Limitations
This paper presents an observational, retrospective analysis and 
relies on the accuracy of the ICD-10 codes in the NIS database 
for its findings. Administrative errors in coding patient comor-
bidities and in- hospital complications may therefore be a source 
of error. We restricted the strategy of using solely postprocedural 
bleeding codes, which reduced the risk of false positives, yet 
certain events may not have been accurately tracked. A number 
of potential confounders, including information on vascular 
access points, arterial access, operator (electrophysiologist vs 
interventional cardiologist), preprocedural anticoagulation, 
were not available and thus could not be included in the adjust-
ments and may represent a source of unmeasured bias. The lack 
of granularity of certain variables precluded the calculation of 
preprocedural bleeding risk such as the HAS- BLED (hyperten-
sion, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile INR, elderly and drugs/alcohol concomi-
tantly) score. Medications at hospital discharge (ie, antiplatelets 
and anticoagulants with or without concomitant antiplatelets) 
were not available. Socioeconomical disparities may have played 
a role on postprocedural management. Lastly, this study is 
limited to in- hospital outcomes where we observed a relatively 
Figure 5 Infographic summarising major findings. White race/ethnicity and zip code median income quartile 4 were the comparator groups. Icons of 
men were chosen for each race/ethnic group for simplicity but do not imply a sex- specific relationship with outcomes. AKI, acute kidney injury; LAAC, 
left atrial appendage closure; MAEs, major adverse events.
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short LOS (median 1 day); hence, complications at 30 days and 
need for readmission are potentially important outcomes that 
were not captured in this study.
CONCLUSION
In this study assessing racial/ethnic disparities in LAAC outcomes, 
aged- based race/ethnicity minorities were under- represented, 
and this disparity was more marked among black patients. More-
over, about half of the population live in neighbourhoods below 
the median income level. Black patients were younger, had the 
higher comorbidity burden and experienced a higher rate of 
postprocedural adverse events as compared with whites patients. 
Low socioeconomic status was not associated with higher rates 
of in- hospital complications following LAAC.
Key messages
What is already known on this subject?
 ► Inequalities in access, management and outcomes among 
patients of various races/ethnicities and socioeconomic status 
has been well documented in various domains of cardiology.
 ► Previous research has shown that both racial and 
socioeconomic disparities exist in atrial fibrillation 
management and transcatheter aortic valve implantation.
What might this study add?
 ► This retrospective cohort study of US hospitalisations found 
that patients of racial/ethnic minority groups, most notably 
blacks, were under- represented recipients of left atrial 
appendage closure (LAAC) procedures as compared with 
white patients.
 ► Black patients were about 5 years younger but presented 
with higher burden of comorbidities.
 ► Adjusted total in- hospital complication rates were higher in 
patients of black race/ethnicity as compared with whites.
How might this impact on clinical practice?
 ► These findings contribute with the understanding of how 
outcomes differ among patients of various racial/ethnic 
groups and socioeconomic status.
 ► Further research is needed to understand the causes behind 
these disparities, the reasons why racial/ethnic minority 
groups make up an under- represented portion of patients 
receiving LAAC in the US and whether longer term differences 
in outcomes and readmission rates are present.
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